ALPX
Alpex Acquisition Corporation Class AstockNASDAQ
alopexx enterprises works with scientists and entrepreneurs to build successful new companies. we invest in novel health care technologies at all stages of development and can serve as a lead investor or collaborate with a group of investors to advance important science. we also have the capabilities to provide management and development expertise where needed. to date, our initial investments have ranged from $1-20m. the alopexx team consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, cmc, toxicology, medical and clinical operations, quality and regulatory affairs. we form collaborations with academic institutions, biotech and pharmaceutical companies to advance our portfolio companies to deliver breakthrough therapies to patients in need. our business model is to invest and develop to an important inflection point and then partner the asset for further development and/or commercialization. portfolio co
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 10.01 | 2026-11-05 | -0.30% | -0.160 |
| 1M | 9.96 | 2026-10-13 | +0.20% | 0.012 |
| 3M | 9.90 | 2026-08-13 | +0.81% | 0.004 |
| 6M | 9.84 | 2026-07-07 | +1.42% | 0.002 |
Alpex Acquisition Corporation Class A (NASDAQ:ALPX) stock price today is $9.98, and today's volume is 85,116. ALPX is up 0.000% today. The 30 day average volume is 63,955. ALPX market cap is $147.63M with 14.79M shares outstanding.